Neupro ( Rotigotine ) : Neupro
Neupro
Your INDEPENDENT source of news about the Neupro
 
FAQ
About Us
Contact us

 

Welcome to Neupro ( Rotigotine ) Health
 

 

Schwarz Pharma announced today that applications for marketing approval for the rotigotine transdermal system, a patch, to treat patients in early stages of Parkinson's disease have been submitted to both, the European Medicines Agency (EMEA) and the U.S. Food and Drug Administration (FDA).

Neupro, with the active ingredient rotigotine, is a novel dopamine receptor-agonist formulated as a continuous transdermal delivery system, a patch. The patch is applied once a day to the skin and administers rotigotine transdermally to the body for 24 hours. Multinational clinical studies with patients in early stages of Parkinson's disease were completed at the end of 2003. More than 1,500 patients with Parkinson’s disease have been treated with Neupro (rotigotine transdermal system) in 15 clinical trials.

 

 

 

This is an independent Information site on Neupro. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.